Real-world Danish registry data show that biologic drug survival in psoriasis differs between biologic-naive and ...
Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...
Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...
The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and ...
Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...
Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong ...
Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased to ...
People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.
Everyday Health on MSN
How does diet affect your psoriasis?
Discover how diet impacts psoriasis. Learn about anti-inflammatory foods like those in the Mediterranean diet and their role ...
Researchers have found in a new study that in a real-world Japanese cohort, deucravacitinib 6 mg provided sustained disease ...
Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback